NCT00548353
Completed
Phase 1
A Randomized, Double-Blind, Placebo Controlled, 2-Period, Fixed-Sequence Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of Orally Administered MK3207 in Patients During and Between Their Acute Migraine Attacks
Overview
- Phase
- Phase 1
- Intervention
- MK3207
- Conditions
- Migraine Disorders
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 22
- Primary Endpoint
- Safety in migraine patients
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
A study to assess safety and PK of an investigational drug in migraine patients during and between migraine attacks.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Non-smoking male or female between 18 to 45 years of age
- •Patient typically has between 2 and 10 migraine attacks per month, rated as moderate or severe
Exclusion Criteria
- •Patient has any other medical conditions other than migraine
Arms & Interventions
1
MK3207 Orally administered to patients with water. During each period (with and without acute migraine).
Intervention: MK3207
Outcomes
Primary Outcomes
Safety in migraine patients
Time Frame: 12 Weeks
Secondary Outcomes
- PK in migraine patients(12 Weeks)
Similar Trials
Recruiting
Not Applicable
Post-marketing Clinical Trial of Elexir(Trigeminal Nerve Electrical Stimulator) for the Acute Treatment of MigraineMigraineNCT06170411Nu Eyne Co., Ltd.100
Completed
Phase 3
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)MigraineEpisodic MigraineHeadacheHeadache, MigraineNCT06004388Click Therapeutics, Inc.110
Completed
Phase 3
Study to Test a Marketed Product in the Treatment of Migraine-associated NauseaMigraineNCT00250458Organon and Co346
Recruiting
Not Applicable
Closed-loop RTMS for Short-term Migraine PreventionMigraine DisordersNCT06735768Brightmind.AI88
Completed
Phase 2
Efficacy and Safety of BGG492 in the Treatment of MigraineMigraineNCT00892203Novartis75